Evidence map›Paper›PMID 30196752›Full record

ArticleCell cycle (Georgetown, Tex.)2018

Elevated expression of NFE2L3 predicts the poor prognosis of pancreatic cancer patients.

Hui Wang, Ming Zhan, Ruimeng Yang, Yongheng Shi, Qiang Liu, Jian Wang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 51 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Identification roles of NFE2L3 in digestive system cancers.Journal of cancer research and clinical oncology · 2024
    Article
  8. New insight into the CNC-bZIP member, NFE2L3, in human diseases.Frontiers in cell and developmental biology · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hui Wanga Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai , China.
Ming Zhana Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai , China.
Ruimeng Yangb The Core Laboratory in Medical Center of Clinical Research, Department of Endocrinology, Shanghai Ninth People's Hospital , Shanghai Jiaotong University School of Medicine , Shanghai , China.
Yongheng Shic Department of Pathology, Renji Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai , China.
Qiang Liuc Department of Pathology, Renji Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai , China.
Jian Wanga Department of Biliary-Pancreatic Surgery, Renji Hospital, School of Medicine , Shanghai Jiao Tong University , Shanghai , China.
Shanghai Jiao Tong University · CNRenji Hospital · CNShanghai Ninth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The highly malignant feature and difficulties for early diagnosis are the key reasons contributing to the poor prognosis of pancreatic cancer (PC) patients. NFE2L3 is a nuclear transcription factor, which has been reported an important biomarker of several tumors. But the role of NFE2L3 in PC remained undefined. Herein, through qPCR and immunohistochemistry, we found a significantly increased NFE2L3 in PC tissues as compared with adjacent non-tumor tissues. While reducing NFE2L3 expression suppressed the invasion abilities of PC cells, elevated NFE2L3 was found associated with lymph node metastasis (P = 0.001; HR = 3.95; 95% CI: 1.70 - 9.17) and advanced TNM stages (P < 0.001; HR = 4.06; 95% CI: 1.74 - 9.46). Consistently, data from both our two cohorts and the TCGA database revealed that higher NFE2L3 PC carriers had worse outcomes than those lower NFE2L3 expressers. Lastly, we confirmed the regulatory role of NFE2L3 on VEGFA, an important player involved in tumor angiogenesis. Collectively, our investigations suggested the oncogenic role of NFE2L3 in PC development and provided the rational for future adding NFE2L3 for the risk assessment of PC patients. ABBREVIATIONS: NFE2L3: NF-E2-related factor 3; UHMK1: U2AF homology motif kinase 1; VEGFA: vascular endothelial growth factor A; GEO: gene expression omnibus; TCGA: The Cancer Genome Atlas; HPDE: human pancreas duct cells; OS: overall survival; IHC: immunohistochemistry; FFPE: formalin-fixed and paraffin-embedded; SEM: standard error of mean.

Indexed as

AgedAged, 80 and overBasic-Leucine Zipper Transcription FactorsBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedNeovascularization, PathologicPancreatic NeoplasmsVascular Endothelial Growth Factor ABasic-Leucine Zipper Transcription FactorsBiomarkers, TumorNFE2L3 protein, humanVascular Endothelial Growth Factor AbiomarkerNFE2L3Pancreatic cancerprognosisVEGFA

Identifiers

PMID30196752
PMCPMC6226237
OpenAlexW2889931773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.